556 related articles for article (PubMed ID: 16374600)
41. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
Denys D; de Geus F; van Megen HJ; Westenberg HG
J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
[TBL] [Abstract][Full Text] [Related]
42. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
[TBL] [Abstract][Full Text] [Related]
43. An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms.
Reznik I; Sirota P
Clin Neuropharmacol; 2000; 23(3):157-60. PubMed ID: 10895399
[TBL] [Abstract][Full Text] [Related]
44. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
Nakamae T
Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
[TBL] [Abstract][Full Text] [Related]
45. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
[TBL] [Abstract][Full Text] [Related]
46. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
Mohr N; Vythilingum B; Emsley RA; Stein DJ
Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
[TBL] [Abstract][Full Text] [Related]
47. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study.
Stryjer R; Budnik D; Ebert T; Green T; Polak L; Weizman S; Spivak B
Clin Neuropharmacol; 2014; 37(3):79-81. PubMed ID: 24824662
[TBL] [Abstract][Full Text] [Related]
48. Predictors of treatment response to fluvoxamine in obsessive-compulsive disorder: an fMRI study.
Sanematsu H; Nakao T; Yoshiura T; Nabeyama M; Togao O; Tomita M; Masuda Y; Nakatani E; Nakagawa A; Kanba S
J Psychiatr Res; 2010 Mar; 44(4):193-200. PubMed ID: 19758599
[TBL] [Abstract][Full Text] [Related]
49. Metacognitive beliefs predict early response to pharmacological treatment in patients with obsessive-compulsive disorder.
Park CI; Kim HW; Jeon S; Hwang EH; Kang JI; Kim SJ
Psychopharmacology (Berl); 2020 Nov; 237(11):3489-3496. PubMed ID: 32748029
[TBL] [Abstract][Full Text] [Related]
50. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.
Pittenger C; Bloch MH; Wasylink S; Billingslea E; Simpson R; Jakubovski E; Kelmendi B; Sanacora G; Coric V
J Clin Psychiatry; 2015 Aug; 76(8):1075-84. PubMed ID: 26214725
[TBL] [Abstract][Full Text] [Related]
51. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study.
Marazziti D; Pfanner C; Dell'Osso B; Ciapparelli A; Presta S; Corretti G; Di Nasso E; Mungai F; Dell'Osso L
J Psychopharmacol; 2005 Jul; 19(4):392-4. PubMed ID: 15982994
[TBL] [Abstract][Full Text] [Related]
52. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder.
Oulis P; Mourikis I; Konstantakopoulos G
Int Clin Psychopharmacol; 2011 Jul; 26(4):221-4. PubMed ID: 21460732
[TBL] [Abstract][Full Text] [Related]
53. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762].
Carey PD; Vythilingum B; Seedat S; Muller JE; van Ameringen M; Stein DJ
BMC Psychiatry; 2005 Jan; 5():5. PubMed ID: 15667657
[TBL] [Abstract][Full Text] [Related]
54. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
55. [Efficacy of fluvoxamine combined with extended-release methylphenidate on treatment-refractory obsessive-compulsive disorder].
Zheng H; Jia F; Guo G; Quan D; Li G; Huang H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Nov; 43(11):1230-1235. PubMed ID: 30643068
[TBL] [Abstract][Full Text] [Related]
56. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control.
Naderi S; Faghih H; Aqamolaei A; Mortazavi SH; Mortezaei A; Sahebolzamani E; Rezaei F; Akhondzadeh S
Psychiatry Clin Neurosci; 2019 Apr; 73(4):169-174. PubMed ID: 30488617
[TBL] [Abstract][Full Text] [Related]
57. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Aboujaoude E; Gamel NN
J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
[TBL] [Abstract][Full Text] [Related]
58. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
[TBL] [Abstract][Full Text] [Related]
59. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study.
Atmaca M; Kuloglu M; Tezcan E; Gecici O
Int Clin Psychopharmacol; 2002 May; 17(3):115-9. PubMed ID: 11981352
[TBL] [Abstract][Full Text] [Related]
60. Plasma fluvoxamine levels and OCD symptoms/response in adult patients.
Marazziti D; Baroni S; Giannaccini G; Piccinni A; Picchetti M; Massimetti G; Schiavi E; Palego L; Catena-Dell'Osso M
Hum Psychopharmacol; 2012 Jul; 27(4):397-402. PubMed ID: 22806821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
